Celltrion's Truxima leads U.S. prescription market in Feb.
--------------------------------------------------------------------
Source: South Korea
Published: 2026-04-07 11:46 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: South Korea, Economy & Finance, Financial Markets, Business & Economy
--------------------------------------------------------------------
Snippet:
SEOUL, April 7 (Yonhap) -- Celltrion Inc., a leading South Korean biopharmaceutical company, said Tuesday its biosimilar Truxima, used to treat blood cancers, claimed the largest share of prescriptions in the United States in February.
--------------------------------------------------------------------